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Abstract
Background: Methotrexate (MTX) and salazosulfapyridine (SASP) are disease-modifying drugs that are commonly
used in the treatment of rheumatoid arthritis (RA), and combination therapy with MTX and SASP is recommended
for RA patients who show an inadequate response to monotherapy with either drug. This study was designed to
examine the interaction between the two drugs from the viewpoint of serum MTX concentration in Japanese RA
patients, who were receiving combination therapy with relatively low doses of MTX and SASP.
Methods: This is a 24-week open-label intervention study of stable RA patients (n = 10) with low disease activity. In
these patients, who had received SASP/MTX combination therapy for at least 12 weeks, SASP was discontinued, and
the patients received MTX monotherapy for the next 24 weeks. The primary outcome was change of serum MTX
concentration at 12 weeks after discontinuation of SASP. Two disease activity markers, simplified disease activity
index (SDAI) and disease activity score-C reactive protein (DAS28-CRP), were assessed as secondary outcomes at
24 weeks after discontinuation of SASP. We also monitored levels of matrix metalloproteinase-3 (MMP-3) and
inflammatory cytokines. Patients were asked to complete a questionnaire after the study.
Results: Serum MTX concentration in RA patients who discontinued SASP increased more than 2-fold within
4 weeks, and the higher level was maintained thereafter. No significant differences were detected in SDAI,
DAS28-CRP, MMP-3 or inflammatory cytokines. Most participants reported no change in physical condition after
withdrawal of SASP, and most preferred MTX monotherapy for future treatment.
Conclusions: Withdrawal of SASP from patients receiving SASP/MTX caused a rapid, marked increase of serum
MTX concentration, without any apparent change in disease parameters or side effects. Our results suggest that
SASP can be discontinued without adverse effects in stable RA patients receiving combination therapy, at least
among Japanese patients receiving relatively low doses of the two drugs.
Trial registration: UMIN000024507. October 21, 2016 retrospectively registered.
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Background
Rheumatoid arthritis (RA) is a chronic, systemic, destruc-
tive joint disease. It occurs most frequently in middle-
aged women, and about 0.5 to 1.0% of the population
suffer from the disease in the industrialized world [1]. At
onset, patients report morning stiffness and painful
swelling of small joints. These symptoms eventually cause
irreversible destruction of bone and cartilage [2], leading
to severe disability in daily life. Therefore, early diagnosis
and early intervention to prevent joint destruction are
important.
The symptoms are caused by inflammatory cytokines,
such as tumor necrosis factor-α (TNF-α) and interleukin-
6 (IL-6). Methotrexate (MTX) and salazosulfapyridine
(SASP) are considered as first-choice drugs to treat RA
[3, 4]. MTX was developed as an anti-cancer drug in
the 1940s, and was subsequently approved for RA in
1999 in Japan; it has a cytostatic effect due to its folic
acid metabolism antagonistic activity, and also has an
anti-inflammatory action by increasing production of
adenosine. There is abundant evidence supporting the
efficacy, economy, and tolerance of MTX in RA pa-
tients [5]. On the other hand, SASP has been used to
treat RA since 1995 in Japan. It has antibacterial and
anti-inflammatory activities, and is an immunomodula-
tor [6]. SASP is often prescribed for RA patients who
show low disease activity or who respond poorly to MTX,
or who have encountered adverse events of MTX. Further,
SASP/MTX combination therapy is often used for RA pa-
tients who do not show an adequate response to mono-
therapy, since it was found in a clinical trial that
combination therapy with MTX and SASP is superior to
either drug alone [7]. The American College of Rheuma-
tology (ACR) and European League Against Rheumatism
(EULAR) recommend combination therapy with disease-
modifying anti-rheumatic drugs (DMARDs) in RA pa-
tients who have high disease activity and poor prognosis
[3, 4]. However, a meta-analysis of combination therapy
with MTX and SASP found no superiority over mono-
therapy with MTX [8].
MTX is absorbed through mainly via the proton-
coupled folate transporter (PCFT) in the upper small
intestine [9, 10]. In vitro transport kinetic analyses indi-
cated that SASP is a potent inhibitor of PCFT-mediated
cellular uptake of MTX [11], suggesting that the absorp-
tion rate of MTX would be reduced in patients receiving
the combination therapy. However, it is not known
whether this change in the pharmacokinetics of MTX also
occurs in RA patients, and if so, whether it influences the
efficacy of SASP/MTX combination therapy.
In this study, we investigated the drug interaction of
MTX and SASP in RA patients, with the aim of estab-
lishing whether SASP discontinuation is a reasonable
strategy in patients receiving the combined therapy. This
information is important, because polypharmacy is un-
desirable on various grounds. For this purpose, we ex-
amined the effect of SASP withdrawal in stable RA
patients who had received the combination therapy.
We measured serum MTX concentration, disease activity
markers and the levels of matrix metalloproteinase-3
(MMP-3) and inflammatory cytokines, as well as adminis-
tering a questionnaire to patients.
Methods
Participant population
Outpatients fulfilling the ACR criteria for diagnosis of
RA were recruited [12]. The main inclusion criteria were
age ≥ 20 years, treatment with SASP/MTX combination
therapy for at least 12 weeks before entry into this study,
and low disease activity, defined as simplified disease ac-
tivity index (SDAI) ≤ 11 [13]. Thirteen patients who met
these criteria agreed to participate in this study, but 3
patients who showed poor compliance were eliminated,
leaving 10 patients (5 men, 5 women). The characteris-
tics of participants at week 0 (discontinuation of SASP)
are summarized in Table 1, i.e., sex, age, duration of RA,
serum creatinine (Cr), blood urea nitrogen (BUN), aspar-
tate aminotransferase (AST), alanine aminotransferase
Table 1 Baseline clinical characteristics of participants
Items Participants
No. of patients (male/female) 10 (5/5)
Age (years) 64.1 ± 10.6
Duration of RA (years) 8.4 ± 11.0
Cr (mg/dL) 0.66 ± 0.12
BUN (mg/dL) 15.6 ± 4.9
AST (IU/L) 20.5 ± 3.3
ALT (IU/L) 23.3 ± 11.6
MCV (fL) 97.8 ± 2.5
CRP (mg/dL) 0.2 ± 0.2
SDAI 5.4 ± 4.0
DAS28-CRP 2.1 ± 0.8
MMP-3 (ng/mL) 130.2 ± 88.6
MTX (mg/week) 7.0 ± 3.0
MTX dosage at first dose each week
4 mg (No. of patients) 5
2 mg (No. of patients) 5
SASP (mg/day) 1000 ± 0
PSL (mg/day) 2.7 ± 2.7
No. of drugs being taken 6.0 ± 2.1
Cr Serum creatinine, BUN blood urea nitrogen, AST aspartate aminotransferase,
ALT alanine aminotransferase, MCV mean corpuscular hemoglobin, CRP C-reactive
protein, SDAI simplified disease activity index, DAS28-CRP disease activity score-C
reactive protein, MMP-3 matrix metalloproteinase-3, MTX methotrexate,
SASP salazosulfapyridine and PSL prednisolone. Data are mean ± SD
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(ALT), mean corpuscular hemoglobin (MCV), C-reactive
protein (CRP), SDAI, disease activity score-CRP (DAS28-
CRP), MMP-3, dosage of MTX, dosage of SASP, dos-
age of prednisolone (PSL), and number of drugs being
taken.
Study design
This prospective multicenter trial of 24 weeks duration
was conducted in three hospitals (Kanazawa University
Hospital, Social Welfare Organization Saiseikai Kanazawa
Hospital, and Japan Community Healthcare Organization
Kanazawa Hospital). The study was approved by the ethics
committee of Kanazawa University, the ethics committee
of Social Welfare Organization Saiseikai Kanazawa
Hospital and the research ethics committee of Japan
Community Healthcare Organization Kanazawa Hospital
(approval number, 1228–2, 2012–002 and 11-01-02, re-
spectively), and informed consent was obtained from all
patients before initiation of the study. This study was con-
ducted in accordance with the Declaration of Helsinki and
Good Clinical Practice Guidelines.
Treatment and observation
Serum MTX concentration was set as the primary out-
come. MTX was administered orally twice or three times
per week (total dosage: 4.0 - 12.0 mg per week). SASP
was administered orally twice a day (total dosage:
1,000 mg per day). Blood samples were taken 2 h after
the first administration of MTX in any given week, be-
cause the time-to-maximum serum MTX concentration
was reported to be 2.0 ± 0.8 h in the case of oral admin-
istration [14]. At baseline (week 0), participants stopped
taking SASP, and continued MTX monotherapy, and
blood samples were taken 4, 8 and 12 weeks later to
measure serum MTX. As secondary outcomes, we mea-
sured SDAI and DAS28-CRP at baseline (week 0) and at
4, 8, 12 and 24 weeks to evaluate disease activity, and
MMP-3 at baseline (week 0) and at 12 and 24 weeks to
estimate the cartilage destruction [15]. We also measured
TNF-α and IL-6 in 4 participants at baseline (week 0) and
at 4, 8 and 12 weeks to examine immunological changes.
We monitored adverse events such as interstitial pneumo-
nia, myelosuppression and infection through the period of
observation. MTX dosage and the regimen of other drugs
were kept unchanged during this study. Adherence was
checked by interviewing the participants and by pill
counting at each hospital visit. The questionnaire was
completed at the end of the study.
Serum MTX concentration assay
Serum was obtained by centrifugation of whole blood at
2,500 rpm for 5 min. The serum MTX concentration
was measured by fluorescence polarization immunoassay
with a TDxFLx analyzer (Abbot Lab., IL., USA).
Evaluation of disease activity markers
We monitored SDAI and DAS28-CRP as markers of
disease activity. SDAI was recommended as a standard
marker by ACR and EULAR in 2011 [16]. SDAI was
calculated from the number of swollen joints among 28
joints (SJ), tender joints among 28 joints (TJ), the pa-
tient’s global assessment of pain on a 10-cm visual ana-
log scale (PG10), the physician’s global assessment of
disease activity on a 10-cm visual analog scale (MDG10)
and CRP, according to the following formula [13]:
SDAI ¼ SJþ TJþ PG10þMDG10þ CRP
SDAI scores were evaluated as follows: ≤3.3, remission;
>3.3 and ≤11, low disease activity; >11 and ≤26, moderate
disease activity; >26, high disease activity [17].
DAS28-CRP has been developed to discriminate between
high and low disease activity as indicated by clinical deci-
sions of rheumatologists since 20 year ago [18]. It was cal-
culated from the number of SJ, TJ, CRP and the patient’s
global assessment of pain on a 100-mm visual analog scale
(PG100), according to the following formula [19]:
DAS28‐CRP ¼ 0:56 ﬃﬃﬃﬃﬃﬃTJp þ 0:28 ﬃﬃﬃﬃﬃSJp þ 0:36
 ln CRP 10þ 1ð Þ þ 0:014
 PG100þ 0:96
DAS28-CRP scores were evaluated as follows: ≤2.3,
remission; >2.3 and ≤2.7, low disease activity; >2.7 and
≤4.1, moderate disease activity; >4.1, high disease
activity [17].
Assay of serum MMP-3, TNF-α and IL-6
Serum was obtained by centrifugation of whole blood at
2,500 rpm for 5 min. MMP-3 was measured by means of
latex agglutination turbidimetry (BML, Inc., Tokyo,
Japan). Serum levels of TNF-α and IL-6 were measured
in 4 participants with ELISA, according to the manufac-
turer’s protocol (R&D Systems, Inc., MN., USA).
Subjective evaluation by participants
We asked participants to complete a short questionnaire
consisting of three questions at the end of the study.
The first question is “Which was better for your physical
condition, the combination therapy or the monotherapy”.
The second question is “Which treatment would you
choose to receive in the future, the combination therapy
or the monotherapy”. The third question is “Please give
the reasons for your choice in question 2”.
Statistical analysis
All data were analyzed using IBM SPSS statistical soft-
ware version 18 for Windows (SPSS Japan Inc., Tokyo,
Japan). One-way repeated measures ANOVA with post
hoc Tukey’s test was used for comparisons of numerical
Okada et al. Journal of Pharmaceutical Health Care and Sciences  (2017) 3:7 Page 3 of 7
values. Data were expressed as the mean ± standard
deviation. P values under 5% were considered to be
significant.
Results
Changes of serum MTX concentration
As shown in Fig. 1, participants in the study had signifi-
cant higher serum MTX concentrations in the MTX
monotherapy phase than in the SASP/MTX combination
phase. The value of MTX concentration at the end of
the combination therapy phase (baseline, week 0) was
0.07 ± 0.04 μmol/L. The corresponding values after with-
drawal of SASP were: 4 weeks, 0.16 ± 0.06 μmol/L;
8 weeks, 0.14 ± 0.04 μmol/L; 12 weeks, 0.17 ± 0.04 μmol/L;
p < 0.005, respectively).
Changes of disease activity
No statistically significant differences were detected in
SDAI (Fig. 2), although there was a tendency of im-
provement at 24 weeks. The baseline value at week 0
was 5.4 ± 4.0 points. Subsequent values were: 4 weeks,
5.9 ± 3.9 points; 8 weeks, 4.5 ± 4.4 points; 12 weeks,
4.9 ± 5.5 points; 24 weeks, 3.2 ± 3.9 points. DAS28-CRP
showed no significant change during the study. The
baseline value at the beginning of the study (week 0)
was 2.1 ± 0.8 points. Subsequent values were: 4 weeks,
2.1 ± 0.7 points; 8 weeks, 1.9 ± 0.9 points; 12 weeks,
1.9 ± 0.9 points; 24 weeks, 1.7 ± 0.7 points).
Changes of serum MMP-3 and cytokine levels
As shown in Fig. 3a, MMP-3 showed no significant
change during the 24-week study (baseline, week 0,
116.1 ± 66.3 ng/mL; 12 weeks, 106.9 ± 76.1 ng/mL;
24 weeks, 102.3 ± 67.6 ng/mL). As shown in Fig. 3b,
there was no statistically significant change of TNF-α or
IL-6 after withdrawal of SASP. The values of TNF-α and
IL-6 at baseline (week 0) were 5.1 ± 7.4 pg/mL and 5.6 ±
4.9 pg/mL, and those after discontinuation of SASP were
3.5 ± 4.7 pg/mL and 4.9 ± 4.1 pg/mL at 4 weeks, 2.9 ±
3.1 pg/mL and 5.2 ± 5.2 pg/mL at 8 weeks, 3.4 ± 4.3 pg/mL
and 5.2 ± 4.7 pg/mL at 12 weeks, respectively.
Subjective evaluation of participants
The questionnaire results are shown in Table 2. Seven
out of 10 participants reported no change in physical
condition after withdrawal of SASP, while the remaining
3 felt better after the withdrawal. Eight out of 10 said
they would prefer MTX monotherapy in future. Interest-
ingly, participants who favored monotherapy in the future
said that a major reason for their choice was to reduce the
number of drugs they were taking, i.e., they saw polyphar-
macy as undesirable.
Occurrence of serious adverse events
None of the participants experienced serious adverse
events in this study. Values of Cr, BUN, AST, ALT and
MCV were unchanged during the study (Cr: 0.66 ±
0.12 mg/dL at baseline (week 0) to 0.67 ± 0.14 mg/dL at
24 weeks, BUN: 15.6 ± 4.9 mg/dL at baseline to 13.7 ±
3.3 mg/dL at 24 weeks, AST: 20.5 ± 3.3 IU/L at baseline
to 20.2 ± 4.1 IU/L at 24 weeks, ALT: 23.3 ± 11.6 IU/L at
baseline to 22.3 ± 14.1 IU/L at 24 weeks, MCV: 97.8 ±
2.5 fL at baseline to 96.0 ± 4.0 fL at 24 weeks).
Fig. 1 Changes of serum MTX concentration. The figure showed
individual serum MTX concentrations at the conclusion of SASP/MTX
combination therapy (baseline, 0 weeks) and at 4, 8 and 12 weeks
after withdrawal of SASP. Horizontal bars represent the mean serum
concentration for all participants (n = 10). Comparisons were made
by one-way repeated measures ANOVA with post hoc Tukey’s test.
*p < 0.005, significantly different from baseline
Fig. 2 Changes of participants’ disease activity scores. The figure
showed the scores of SDAI and DAS28-CRP at the conclusion of
SASP/MTX combination therapy (baseline, 0 weeks), and at 4, 8, 12
and 24 weeks after withdrawal of SASP. The squares indicated SDAI
(■). The triangles indicated DAS28-CRP (▲). Data are mean ± SD
(bars) for all assigned participants (n = 10). Comparisons were made
by one-way repeated measures ANOVA with post hoc Tukey’s test
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Discussion
We found that the serum MTX concentration in RA pa-
tients who were taking SASP/MTX combination therapy
increased more than 2-fold when SASP was discontinued,
and the increase was maintained thereafter. It was re-
ported that improvement of inflammatory markers in RA
patients is correlated with the time for which the serum
MTX concentration is over 0.02 μM [20]. In this study, we
measured only the maximum serum MTX concentration
since it was not feasible to carry out frequent blood
samplings in outpatients. Three out of 10 participants
receiving the combination therapy had Cmax values of
MTX lower than 0.02 μM. But, after withdrawal of SASP,
all participants showed a higher maximum serum MTX
concentration than 0.02 μM. Furthermore, the MTX con-
centration at baseline in this study was lower than the
average serum MTX concentration in Japanese RA pa-
tients who received weekly pulse low-dose MTX therapy
in a prior study [14], supporting the idea that coadminis-
tration of SASP tends to decrease MTX concentration.
It is noteworthy that SDAI and TNF-α tended to
decrease after SASP withdrawal, and no patient showed
exacerbation of RA status (Figs. 2 and 3). These results
suggest that the increased serum MTX concentration
following SASP withdrawal at least compensated for the
loss of the efficacy of the SASP. These findings appear to
be inconsistent with the ACR and EULAR recommen-
dations for combination therapy with MTX and SASP
[3, 4]. However, the apparent contradiction may be ex-
plained by differences in the dosages of MTX and
SASP. Our participants received an average MTX dos-
age of 7.0 mg/week, compared with 12.5 mg/week in
Capell et al.’s clinical trial in the UK [7]. Similarly, the
average SASP dosage in our participants was 1,000 mg/day,
compared with 2,500 mg/day in Capell et al.’s clinical trial
[7]. In other words, Japanese RA patients take smaller
dosages of MTX and SASP than those recommended in
ACR and EULAR. It seems likely that these relatively low
MTX and SASP dosages are unsuitable for combination
therapy for RA patients.
The reason for the increased serum MTX concentra-
tion following SASP withdrawal may be that SASP is a
potent inhibitor of PCFT, which plays an essential role
in MTX absorption from the upper small intestine.
Indeed, the influx of MTX is inhibited by SASP in hu-
man alveolar epithelial cell line A549 expressing PCFT
Fig. 3 Changes of serum MMP-3 and cytokine levels. a The left figure shows serum MMP-3 (□) levels (mean ± SD (bars), n = 10) at the conclusion
of SASP/MTX combination therapy (baseline, 0 weeks), and at 12 and 24 weeks after withdrawal of SASP. b The right figure shows serum TNF-α
(●) and the serum IL-6 (○) levels (mean ± SD (bars), n = 4) at the conclusion of SASP/MTX combination therapy (baseline, 0 weeks), and at 4, 8 and
12 weeks after withdrawal of SASP. Comparisons were made by one-way repeated measures ANOVA with post hoc Tukey’s test
Table 2 Questionnaire: subjective evaluation by participants
Questionnaire No. of participants
Question 1: Which was better for your
physical condition, the combination therapy
or the monotherapy? (n = 10)
Combination therapy 0
Monotherapy 3
I found no difference 7
Question 2: Which treatment would you choose
to receive in the future, the combination therapy
or the monotherapy? (n = 10)
Combination therapy 0
Monotherapy 8
Follow primary physician’s advice. 2
Question 3: Please give the reasons for your choice
in question 2. (n = 8, multiple answers allowed)
I want to reduce the number of drugs I am taking 6
I felt better with monotherapy 3
I am not worried about side effects 2
The cost of drugs is important to me 1
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mRNA [10]. It was also reported that the IC50 of SASP
for MTX uptake in HEK293 cells stably expressing hu-
man PCFT was 60.4 μM [11]. In the clinical situation,
the nominal SASP concentration might be 5 mM or
higher in the small intestine when 500 mg of SASP is
taken with 200 mL of water, and so the concentration of
SASP should be more than sufficient to inhibit the
absorption of MTX via PCFT. We consider that the re-
covery of PCFT function plays a key role in the recovery
of serum MTX concentration after SASP withdrawal
from SASP/MTX combination therapy. A possible coun-
termeasure to overcome the MTX-suppressing effect of
combination therapy might be to take SASP only in the
during the intervening periods which not to take MTX
under weekly pulse low-dose MTX therapy, since orally
administered MTX was rapidly and almost completely
absorbed [21].
The results of the questionnaire indicated that most
participants preferred MTX monotherapy. Thus, on the
basis of both objective and subjective evaluations, it
would be reasonable to withdraw SASP in stable RA pa-
tients receiving SASP/MTX combination therapy. In this
study, the resulting increase of serum MTX concentra-
tion did not cause severe adverse events. However, care
is necessary in the case of SASP withdrawal, because
MTX-associated adverse events such as bone marrow
suppression and liver injury are MTX dose-dependent.
Further study will be needed to identify the optimum
treatment in RA patients undergoing DMARDs therapy.
Recently, polypharmacy has become a significant
social problem in our aging society [22]. Schuler et al.’s
reported that the average number of prescriptions in 543
patients who entered hospital in Austria was 7.5 ± 3.8.
They identified possible drug-drug interaction in 65.8%
and adverse events in 17.8% of the patients [23]. In
another study, the incidence of adverse events was 6.5%
when patients took 1–3 drugs, and 13.1% when they
took 6–7 drugs [24]. It has also been demonstrated in a
clinical trial that the incidence of nausea was increased
in RA patients taking SASP/MTX combination therapy
compared with MTX monotherapy [25]. Polypharmacy
is a particularly important problem for RA patients, who
often take large numbers of drugs, such as biological
agents, DMARDs, prednisolone (PSL), non-steroidal anti-
inflammatory drugs, stomach drugs and anti-osteoporosis
drugs. Among our stable RA patients, the average number
of drugs was 6.0 ± 2.1. Thus, if we can reduce polyphar-
macy by replacing SASP/MTX combination therapy with
MTX monotherapy based on the results of this study,
there could be a significant benefit for RA patients.
The present study has several important limitations.
First, the number of cases was small. Secondly, we used
an open label design, which might have introduced sub-
jective bias. Thirdly, we did not examine changes of
methotrexate-polyglutamates, which accumulate in
cells during MTX administration, though a relationship
between disease activity of RA and methotrexate-
polyglutamates concentration was recently reported
[26]. Nevertheless, we believe the results of this small-
scale study warrant a more detailed re-examination of
the relative merits of SASP/MTX combination therapy
and MTX monotherapy.
Conclusions
The results of this small-scale open-label clinical trial in-
dicate that the MTX concentration increased markedly
upon discontinuation of SASP, with no apparent change
of efficacy or side effects. Therefore, we suggest that it is
reasonable to withdraw SASP in stable RA patients re-
ceiving SASP/MTX combination therapy, at least in
Japanese RA patients receiving relatively low doses of
the two agents. This would have the advantage of redu-
cing the potential adverse effects of polypharmacy.
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